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Neuroblastoma is the most common extracra-
nial solid tumor in childhood and the most fre-
quently diagnosed malignancy during infancy. It is
rare in adults and more than 96% of patients di-
agnosed with neuroblastoma are less than 10 years
of age.1 Most neuroblastoma develops sporadi-
cally and only 1–2% of newly diagnosed neuro-
blastoma cases have a family history.2 It accounts
for 5–6% of all childhood cancer and there are
20–30 new cases per year in Taiwan (data from
Childhood Cancer Foundation, R.O.C., unpub-
lished data).
This embryonic neoplasm derives from neural
crest precursor cells of the peripheral sympathetic
nervous system and usually arises in a paraspinal
sympathetic ganglion or the adrenal gland.3 The
histological composition of neuroblastoma varies
from primitively undifferentiated neuroblasts
without discernible neuropils to mature ganglion
cells with abundant neuropils.4 The clinical behav-
ior of neuroblastoma is also remarkable, with a
broad spectrum, and can be categorized into three
distinct patterns: (1) life-threatening progression;
(2) spontaneous regression; and (3) spontaneous
maturation to benign ganglioneuroma. Therefore,
neuroblastoma is a heterogeneous tumor with
diverse biological characteristics, which range from
highly malignant tumors with very poor out-
comes to the most benign ganglioneuroma or
neuroblastoma with spontaneous regression and
hence favorable prognosis.3
The heterogeneous clinical behavior of neuro-
blastoma is usually closely associated with hetero-
geneous genetic changes and biological features.1
Somatic changes, such as gain or loss of alleles,
and activation of oncogenes, or variations in
tumor-cell ploidy have been shown to be crucial
in the development of sporadic neuroblastoma.1
According to the accumulated research data on the
genetics of neuroblastoma, there are at least two
genetic subsets of neuroblastoma, which are hig-
hly associated with clinical behavior. The first ge-
netic type of neuroblastoma has a hyperdiploid or
near-triploid karyotype, with very few or no cyto-
genetic rearrangements. The nerve growth factor
receptor TrkA is usually highly expressed on this
type of tumor, and leads neuroblastoma cells to
apoptosis or differentiation, depending on the
presence of nerve growth factor. Patients with
this type of neuroblastoma are usually less than
1 year of age with localized disease, and have a
very good outcome.1 This type of neuroblastoma is
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categorized as a low-risk disease upon treatment.5
In contrast, the other genetic type of neuroblas-
toma has a near-diploid or tetraploid karyotype
with structural aberrations, which might affect the
oncogenes or tumor suppressor genes on chromo-
somes 1p, 11q and 17q, including MYCN gene.1
The most aggressive subset in this type of neu-
roblastoma has MYCN amplification, and usu-
ally loss of heterozygosity of chromosome 1p.
Brain-derived neurotrophic factor and its recep-
tor TrkB are frequently expressed on this type 
of tumor, and presumably form an autocrine sur-
vival pathway that confers a selective advantage
on neuroblastoma cells. Patients with this type
of neuroblastoma are usually more than 1 year
of age with an advanced disease stage, and have a
very poor outcome.1 This type of neuroblastoma is
categorized as a high-risk disease upon treatment.5
Therefore, biological characteristics are crucial
for the prognosis of neuroblastoma, in addition
to traditional clinicopathological factors of age,
tumor stage, and tumor histology.
The current treatment for neuroblastoma is
risk-adapted according to the classification system
established by the International Neuroblastoma
Risk Group.5 This system combines various clinico-
pathological and biological prognostic factors, in-
cluding patient age, disease stage, tumor histology,
and biomarkers including MYCN amplification,
11q aberration, and tumor ploidy, for risk-group
assignment and treatment stratification.6 In ad-
dition to chemotherapy intensity, molecular bio-
markers might also affect the surgical decisions
in neuroblastoma treatment.7 Furthermore, we
recently identified several biomarkers with prog-
nostic significance in neuroblastoma,8 including
calreticulin, glucose-regulated protein 78, and
glucose-regulated protein 75. These markers fur-
ther stratify neuroblastoma patients for more ap-
propriate therapeutic strategies, and might serve
as a target for the treatment of neuroblastoma in
the future.
The conventional treatment for patients with
high-risk neuroblastoma consists of intensive cyto-
toxic chemotherapy, external beam radiotherapy,
or radical surgery with or without autologous bone
marrow transplantation.3 Nevertheless, patients
with high-risk neuroblastoma still have a very poor
prognosis with a long-term survival of < 40%.3 As
more biological characteristics of neuroblastoma
are identified, more therapies according to these
biological targets are developed for clinical prac-
tice. For example, differentiation therapy using
13-cis-retinoic acid has been shown to improve
outcome of high-risk neuroblastoma after bone
marrow transplantation, with only minimal tox-
icity.1 Radioactive meta-iodobenzylguanidine is
useful for specific diagnostic imaging and targeted
radiotherapy of neuroblastoma.3 Disialoganglio-
side-targeted monoclonal antibodies have been
assessed in early phase trials, and are being studied
with synergistic cytokines in phase III trials in
newly diagnosed neuroblastoma patients.3 ALK
has recently been identified as a major familial
neuroblastoma predisposing gene.2 However, ac-
tive mutations of ALK are not only in germline, but
are also somatically acquired in 6–12% of sporadic
cases of neuroblastoma.2,9 These findings suggest
ALK as a tractable therapeutic target in neuroblas-
toma.2,9 Other biologically based therapies for
neuroblastoma, such as induction of apoptosis, in-
hibition of angiogenesis, metronomic therapy, and
inhibition of tyrosine kinase, are also under devel-
opment, which might potentially lead to a more
specific but less toxic treatment in the future.1,3
Finally, neuroblastoma is an embryonic neo-
plasm that is derived from neural crest precursor
cells; therefore, its cells possess the properties of
further differentiation as well as neuronal charac-
teristics. Neuroblastoma might serve as a model
for research on the developmental biology of the
nervous system as well as neurological diseases.
For example, neuroblastoma cells have been used
as a tool for in vitro validation of many studies
that have focused on Alzheimer’s or psychological
disease.10 The crosstalk between different fields
of research can bring unexpected practical appli-
cations. Recently, we have demonstrated that a γ-
secretase inhibitor, originally used in the treatment
of Alzheimer’s disease, was also effective in re-
ducing tumor size of neuroblastoma in an animal
study.11 Furthermore, neuroblastoma might also
H.H. Chang, W.M. Hsu
556 J Formos Med Assoc | 2010 • Vol 109 • No 8
Perspectives on neuroblastoma
J Formos Med Assoc | 2010 • Vol 109 • No 8 557
serve as a model disease for research into other
childhood cancers, because genetic and biological
analysis of neuroblastoma cells might provide
crucial information for guidance of optimal pa-
tient management.1 A single array-based platform
for genetic and molecular profiling that can reli-
ably and accurately detect allelic gains or losses,
as well as MYCN amplification, and tumor ploidy
of neuroblastoma at diagnosis, can be easily re-
produced between various cooperative groups 
or countries.6 This could help to identify genetic
signatures of neuroblastoma with prognostic and
pathogenetic significance, and identify new mo-
lecular targets for novel therapies.
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